US equities
|
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Kura Oncology, Inc. - Common Stock
(NQ:
KURA
)
10.39
-0.21 (-1.93%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kura Oncology, Inc. - Common Stock
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
May 12, 2026
From
Kura Oncology, Inc.
Via
GlobeNewswire
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
April 17, 2026
From
Kura Oncology, Inc.
Via
GlobeNewswire
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
January 11, 2026
From
Kura Oncology, Inc.
Via
GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Kura Oncology Inc. (NASDAQ: KURA) is a Stock Spotlight on 3/6
March 06, 2024
Via
Investor Brand Network
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Kura Oncology Inc. (NASDAQ: KURA) Near the Top of Equities by Percentage Gain on 1/24
January 24, 2024
Via
Investor Brand Network
7 Best Cancer Stocks to Invest in Now
July 28, 2023
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.
Via
MarketBeat
Topics
Death
Kura Oncology, Inc. (NASDAQ:KURA) Investor Notice: Investigation over Potential Wrongdoing
↗
March 04, 2022
San Diego, CA -- (SBWIRE) -- 03/04/2022 -- Certain directors of Kura Oncology, Inc are under investigation over potential breaches of fiduciary duties.
Via
SBWire
NASDAQ:KURA Investor Notice: Investigation over Possible Securities Laws Violations by Kura Oncology, Inc.
↗
December 09, 2021
San Diego, CA -- (SBWIRE) -- 12/09/2021 -- Kura Oncology, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
February 02, 2022
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials...
Via
FinancialNewsMedia